CARA (Cara Therapeutics) Common Stock : $0.05 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Common Stock?

Cara Therapeutics's quarterly common stock stayed the same from Mar. 2024 ($0.05 Mil) to Jun. 2024 ($0.05 Mil) and stayed the same from Jun. 2024 ($0.05 Mil) to Sep. 2024 ($0.05 Mil).

Cara Therapeutics's annual common stock stayed the same from Dec. 2021 ($0.05 Mil) to Dec. 2022 ($0.05 Mil) but then increased from Dec. 2022 ($0.05 Mil) to Dec. 2023 ($0.05 Mil).

Cara Therapeutics Common Stock Historical Data

The historical data trend for Cara Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Common Stock Chart

Cara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.05

Cara Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															0.05	0.05	0.05	0.05	0.05

Cara Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Cara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0HTC:UK 69C:Germany

Address

400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Executives

Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Joana Goncalves	officer: Chief Medical Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion	officer: Sec'y; Chief Compliance & G.C.	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Menzaghi Frederique Ph.d.	officer: VP-Research & Development	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ryan D Maynard	officer: Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Moltke Lisa Von	director	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum	director	675 ALMANOR AVE, SUNNYVALE CA 94085
Csl Ltd	10 percent owner
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr	director
Thomas Charles Reilly	officer: Chief Financial Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd.	10 percent owner	RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027